

# Paul S Haber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1876305/publications.pdf>

Version: 2024-02-01

208  
papers

6,917  
citations

76031

42  
h-index

87275

74  
g-index

212  
all docs

212  
docs citations

212  
times ranked

8560  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. <i>Addiction</i> , 2022, 117, 382-391.	1.7	22
2	Daily experiences of hangover severity and food consumption in young adults. <i>British Journal of Health Psychology</i> , 2022, 27, 468-483.	1.9	1
3	Variability in insulin pharmacokinetics following high-dose insulin therapy. <i>Clinical Toxicology</i> , 2022, 60, 389-391.	0.8	2
4	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2022, 76, 275-282.	1.8	33
5	Support for Aboriginal health services in reducing harms from alcohol: 2-year service provision outcomes in a cluster randomized trial. <i>Addiction</i> , 2022, 117, 796-803.	1.7	6
6	Effects of service-wide support on regularity of alcohol screening of clients in Australian Aboriginal and Torres Strait Islander Community Controlled Health Services: a cluster randomised trial. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 13.	1.2	0
7	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence. <i>Frontiers in Global Women S Health</i> , 2022, 3, 807269.	1.1	4
8	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. <i>Sports Medicine - Open</i> , 2022, 8, 27.	1.3	10
9	More than three times as many Indigenous Australian clients at risk from drinking could be supported if clinicians used AUDIT-C instead of unstructured assessments. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 23.	1.2	3
10	A pilot study of a text message and online brief contact intervention following self-harm or a suicide attempt: A mixed methods evaluation. <i>General Hospital Psychiatry</i> , 2022, 76, 1-2.	1.2	2
11	The evaluation of the role of technology in the pathways to comorbidity care implementation project to improve management of comorbid substance use and mental disorders. <i>Journal of Multimorbidity and Comorbidity</i> , 2022, 12, 263355652210969.	0.8	3
12	Alcohol use disorder and the gut. <i>Addiction</i> , 2021, 116, 658-667.	1.7	19
13	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. <i>Psychopharmacology</i> , 2021, 238, 1291-1302.	1.5	19
14	Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of Randomized Controlled Trials. <i>Alcohol and Alcoholism</i> , 2021, 56, 17-27.	0.9	7
15	Randomised controlled trial of integrated cognitive behavioural treatment and motivational enhancement for comorbid social anxiety and alcohol use disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 207-220.	1.3	8
16	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021, 73, 1920-1931.	3.6	54
17	How intoxicated are you? Investigating self and observer intoxication ratings in relation to blood alcohol concentration. <i>Drug and Alcohol Review</i> , 2021, 40, 1173-1177.	1.1	4
18	What are people saying on social networking sites about the Australian alcohol consumption guidelines?. <i>Medical Journal of Australia</i> , 2021, 214, 105.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Support can increase use of the AUDITâ€ in Australian Aboriginal Community Controlled Health Services: a cluster randomized trial. <i>Addiction</i> , 2021, 116, 2304-2315.	1.7	8
20	A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. <i>Implementation Science</i> , 2021, 16, 22.	2.5	20
21	New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1291-1303.	0.9	18
22	Should we be using eâ€ vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. <i>Drug and Alcohol Review</i> , 2021, 40, 1356-1357.	1.1	2
23	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. <i>European Neuropsychopharmacology</i> , 2021, 46, 28-36.	0.3	10
24	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. <i>JAMA Network Open</i> , 2021, 4, e219041.	2.8	55
25	Are bottle shops using Twitter to increase advertising or encourage drinking during COVIDâ€19?. <i>Australian and New Zealand Journal of Public Health</i> , 2021, 45, 391-393.	0.8	0
26	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patientsâ€ experiences in Australia. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108959.	1.6	33
27	Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108420.	1.5	2
28	The role of clinical supervision in implementing evidence-based practice for managing comorbidity. <i>Clinical Supervisor, The</i> , 2021, 40, 158-177.	1.1	7
29	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021, 116, 106-115.	0.2	25
30	Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). <i>Journal of Dual Diagnosis</i> , 2021, 17, 304-312.	0.7	6
31	Treatment of alcohol problems: current status and future directions. <i>Medical Journal of Australia</i> , 2021, 215, 315-316.	0.8	3
32	Gastrointestinal Disorders Related to Alcohol and Other Drug Use. , 2021, , 1077-1097.		2
33	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study. <i>Addiction Biology</i> , 2020, 25, e12702.	1.4	6
34	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs preâ€ and postâ€ universal access to directâ€ acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	1.0	39
35	Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 111-117.	0.8	7
36	Designing, implementing and evaluating the overdose response with takeâ€ home naloxone model of care: An evaluation of client outcomes and perspectives. <i>Drug and Alcohol Review</i> , 2020, 39, 55-65.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Australian treatment outcome study: protocol for the 18â€“20-year follow-up of a prospective longitudinal cohort examining the natural history of heroin dependence and associated mortality, psychiatric and physical health, and health service use. <i>BMJ Open</i> , 2020, 10, e039226.	0.8	5
38	Alcohol use disorder and circulating cytokines: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020, 89, 501-512.	2.0	44
39	Evidence based models of care for the treatment of alcohol use disorder in primary health care settings: a systematic review. <i>BMC Family Practice</i> , 2020, 21, 260.	2.9	9
40	Genetic Polymorphisms on OPRM1, DRD2, DRD4, and COMT in Young Adults: Lack of Association With Alcohol Consumption. <i>Frontiers in Psychiatry</i> , 2020, 11, 549429.	1.3	4
41	Implementation of evidence-based practice for alcohol and substance use disorders: protocol for systematic review. <i>Systematic Reviews</i> , 2020, 9, 25.	2.5	13
42	Baclofen modulates cardiovascular responses to appetitive cues in treatmentâ€seeking alcohol use disorder individuals. <i>Human Psychopharmacology</i> , 2020, 35, e2722.	0.7	7
43	Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC/cannabis extract for refractory chemotherapy-induced nausea and vomiting (CINV).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12008-12008.	0.8	0
44	Comment on pill testing review. <i>Internal Medicine Journal</i> , 2020, 50, 1596-1597.	0.5	2
45	GABAB Receptors and Alcohol Use Disorders: Clinical Studies. <i>Current Topics in Behavioral Neurosciences</i> , 2020, , 195-212.	0.8	6
46	Development of a joint mental-health and drug health assessment unit and short-stay unit. <i>Australasian Psychiatry</i> , 2019, 27, 374-377.	0.4	9
47	Cue Exposure Therapy for Alcohol Use Disorders: What Can Be Learned from Exposure Therapy for Anxiety Disorders?. <i>Substance Use and Misuse</i> , 2019, 54, 2053-2063.	0.7	25
48	Vitamin B <sub>12</sub> supplementation futile for preventing demyelination in ongoing nitrous oxide misuse. <i>Medical Journal of Australia</i> , 2019, 211, 428.	0.8	15
49	Detection of <sup>9</sup> THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two pointâ€collection testing devices. <i>Drug Testing and Analysis</i> , 2019, 11, 1486-1497.	1.6	32
50	A pilot study of escape, avoidance, and approach behaviors in treated alcohol-dependent males. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 601-614.	0.8	3
51	Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment. <i>Substance Use and Misuse</i> , 2019, 54, 1589-1598.	0.7	14
52	Longâ€term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outâ€patients with opioid use disorder. <i>Addiction</i> , 2019, 114, 1416-1426.	1.7	75
53	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724.	1.5	130
54	Identification of smoking status in the Census is needed, but what about the healthcare system?. <i>Australian and New Zealand Journal of Public Health</i> , 2019, 43, 96.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial. <i>Alcohol and Alcoholism</i> , 2019, 54, 272-278.	0.9	9
56	Systematic Reviews of Mindfulness and Acceptance and Commitment Therapy for Alcohol Use Disorder: Should we be using Third Wave Therapies?. <i>Alcohol and Alcoholism</i> , 2019, 54, 159-166.	0.9	44
57	118â€¦Case series: subacute combined degeneration of the spinal cord in vitamin B12-replete recreational nitrous oxide abusers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A38.2-A39.	0.9	0
58	Supporting Aboriginal Community Controlled Health Services to deliver alcohol care: protocol for a cluster randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e030909.	0.8	12
59	Evidence-based models of care for the treatment of alcohol use disorder in primary health care settings: protocol for systematic review. <i>Systematic Reviews</i> , 2019, 8, 275.	2.5	3
60	Executive Functioning Moderates Responses to Appetitive Cues: A Study in Severe Alcohol Use Disorder and Alcoholic Liver Disease. <i>Alcohol and Alcoholism</i> , 2019, 54, 38-46.	0.9	11
61	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series. <i>Alcohol and Alcoholism</i> , 2019, 54, 73-78.	0.9	10
62	Impact of acutely behavioural disturbed patients in the emergency department: A prospective observational study. <i>EMA - Emergency Medicine Australasia</i> , 2019, 31, 387-392.	0.5	28
63	Examining Perceived Stress, Childhood Trauma and Interpersonal Trauma in Individuals With Drug Addiction. <i>Psychological Reports</i> , 2019, 122, 433-450.	0.9	55
64	â€Nurse specialisingâ€™: Direct nursing observation in the emergency department compared to other wards of an urban teaching hospital in Sydney. <i>Australasian Psychiatry</i> , 2018, 26, 276-280.	0.4	4
65	Translating Evidence-Based Practice for Managing Comorbid Substance Use and Mental Illness Using a Multimodal Training Package. <i>Journal of Dual Diagnosis</i> , 2018, 14, 111-119.	0.7	13
66	Characteristics of Suicide Attempters and Ideators in a Clinical Sample of Substance Users. <i>Substance Use and Misuse</i> , 2018, 53, 1811-1818.	0.7	2
67	Vertical transmission of hepatitis C: Testing and healthâ€care engagement. <i>Journal of Paediatrics and Child Health</i> , 2018, 54, 647-652.	0.4	6
68	Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. <i>British Journal of Psychiatry</i> , 2018, 212, 362-369.	1.7	87
69	Biased and less sensitive: A gamified approach to delay discounting in heroin addiction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 139-150.	0.8	27
70	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. <i>Alcohol</i> , 2018, 66, 1-7.	0.8	13
71	Evaluation of a novel method for the analysis of alcohol biomarkers: Ethyl glucuronide, ethyl sulfate and phosphatidylethanol. <i>Alcohol</i> , 2018, 67, 7-13.	0.8	33
72	Applications and Challenges for the Use of Phosphatidylethanol Testing in Liver Disease Patients (Mini) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.48	20

#	ARTICLE	IF	CITATIONS
73	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018, 5, 957-960.	3.7	94
74	Baclofen Response in Alcohol Dependent Patients Concurrently Receiving Antidepressants: Secondary Analysis From the BacALD Study. <i>Frontiers in Psychiatry</i> , 2018, 9, 576.	1.3	5
75	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	1.1	5
76	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). <i>BMJ Open</i> , 2018, 8, e020745.	0.8	16
77	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. <i>Current Addiction Reports</i> , 2018, 5, 287-296.	1.6	7
78	Moderation of baclofen response by a GABA <sub>B</sub> receptor polymorphism: results from the BacALD randomized controlled trial. <i>Addiction</i> , 2018, 113, 2205-2213.	1.7	19
79	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 667-675.	1.9	20
80	Harnessing advances in computer simulation to inform policy and planning to reduce alcohol-related harms. <i>International Journal of Public Health</i> , 2018, 63, 537-546.	1.0	21
81	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). <i>Trials</i> , 2018, 19, 443.	0.7	5
82	Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking. <i>Frontiers in Psychiatry</i> , 2018, 9, 412.	1.3	9
83	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
84	Psychostimulant-related health service demand in an inner-city hospital, 2012-2015. <i>Public Health Research and Practice</i> , 2018, 28, .	0.7	1
85	Intolerance of uncertainty and conditioned place preference in opioid addiction. <i>PeerJ</i> , 2018, 6, e4775.	0.9	9
86	Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10128-TPS10128.	0.8	0
87	Alcohol Related Harm: Knowledge Assessment of Medical and Nursing Staff in a General Hospital. , 2018, 55, 32-36.		1
88	Preliminary results of a controlled educational intervention on alcohol related harm among medical students with a 12-month follow-up. , 2018, 55, 37-39.		0
89	Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 23-25.	1.5	17
90	Pharmacotherapeutic agents in the treatment of methamphetamine dependence. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 563-578.	1.9	97

#	ARTICLE	IF	CITATIONS
91	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. <i>Drug and Alcohol Dependence</i> , 2017, 181, 132-139.	1.6	27
92	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. <i>Journal of Addiction Medicine</i> , 2017, 11, 10-18.	1.4	9
93	Reward and punishment-based compound cue learning and generalization in opiate dependency. <i>Experimental Brain Research</i> , 2017, 235, 3153-3162.	0.7	3
94	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. <i>Mental Health and Physical Activity</i> , 2017, 13, 57-67.	0.9	5
95	Learning and generalization from reward and punishment in opioid addiction. <i>Behavioural Brain Research</i> , 2017, 317, 122-131.	1.2	27
96	Intolerance of uncertainty in opioid dependency – Relationship with trait anxiety and impulsivity. <i>PLoS ONE</i> , 2017, 12, e0181955.	1.1	28
97	A Mobile Text Message Intervention to Reduce Repeat Suicidal Episodes: Design and Development of Reconnecting After a Suicide Attempt (RAFT). <i>JMIR Mental Health</i> , 2017, 4, e56.	1.7	27
98	Alcoholic Liver Disease in Asia, Europe, and North America. <i>Gastroenterology</i> , 2016, 150, 1786-1797.	0.6	133
99	National trends in alcohol pharmacotherapy: Findings from an Australian claims database. <i>Drug and Alcohol Dependence</i> , 2016, 166, 254-257.	1.6	34
100	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAH C II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	0.6	6
101	Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. <i>Transplantation Direct</i> , 2016, 2, e104.	0.8	19
102	The impact of an automatic syringe dispensing machine in inner-city Sydney, Australia: No evidence of a “honey-pot” effect. <i>Drug and Alcohol Review</i> , 2016, 35, 637-643.	1.1	8
103	The Reluctance of Liver Transplant Participants with Alcoholic Liver Disease to Participate in Treatment for Their Alcohol Use Disorder: An Issue of Treatment Matching?. <i>Alcoholism Treatment Quarterly</i> , 2016, 34, 233-251.	0.5	7
104	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. <i>Addiction</i> , 2016, 111, 311-319.	1.7	63
105	Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. <i>International Journal of Drug Policy</i> , 2016, 27, 121-126.	1.6	11
106	Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. <i>Journal of Clinical Virology</i> , 2016, 74, 66-72.	1.6	11
107	Probabilistic reward- and punishment-based learning in opioid addiction: Experimental and computational data. <i>Behavioural Brain Research</i> , 2016, 296, 240-248.	1.2	51
108	Alcohol use disorders. <i>Lancet</i> , The, 2016, 387, 988-998.	6.3	277

#	ARTICLE	IF	CITATIONS
109	The impact of alcohol pharmacotherapies on public health in Australia is limited by low prescribing rates. <i>Public Health Research and Practice</i> , 2016, 26, .	0.7	5
110	Brief Report: Genetics of Alcoholic Cirrhosisâ€” <scp>G</scp>enom<scp>ALC</scp> Multinational Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 836-842.	1.4	29
111	Circulating Lipids Are Associated with Alcoholic Liver Cirrhosis and Represent Potential Biomarkers for Risk Assessment. <i>PLoS ONE</i> , 2015, 10, e0130346.	1.1	33
112	Alcopops, taxation and harm: a segmented time series analysis of emergency department presentations. <i>BMC Public Health</i> , 2015, 15, 468.	1.2	35
113	Harmonizing Post-Market Surveillance of Prescription Drug Misuse: A Systematic Review of Observational Studies Using Routinely Collected Data (2000â€”2013). <i>Drug Safety</i> , 2015, 38, 553-564.	1.4	15
114	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. <i>European Respiratory Journal</i> , 2015, 46, 1202-1205.	3.1	11
115	Hepatitis B vaccination for people who inject drugs. <i>Lancet, The</i> , 2015, 385, 115.	6.3	2
116	Hippocampal glutamate is increased and associated with risky drinking in young adults with major depression. <i>Journal of Affective Disorders</i> , 2015, 186, 95-98.	2.0	25
117	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. <i>International Journal of Drug Policy</i> , 2015, 26, 1094-1102.	1.6	18
118	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	1.6	44
119	The Clinical and Theoretical Basis for Integrated Cognitive Behavioral Treatment of Comorbid Social Anxiety and Alcohol Use Disorders. <i>Cognitive and Behavioral Practice</i> , 2015, 22, 504-521.	0.9	22
120	An overview of the patterns of prescription opioid use, costs and related harms in <scp>A</scp>ustralia. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1159-1166.	1.1	172
121	Overview of Substance Use and Treatment from Australia. <i>Substance Abuse</i> , 2014, 35, 304-308.	1.1	8
122	Quantitation of fibroblast activation protein (FAP)â€™specific protease activity in mouse, baboon and human fluids and organs. <i>FEBS Open Bio</i> , 2014, 4, 43-54.	1.0	89
123	The efficacy of an opportunistic cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk: A multisite randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 130-140.	1.6	27
124	A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners. <i>PLoS ONE</i> , 2014, 9, e87564.	1.1	38
125	Osteopontin is an important mediator of alcoholic liver disease<i>via</i>hepatic stellate cell activation. <i>World Journal of Gastroenterology</i> , 2014, 20, 13088.	1.4	44
126	A novel mechanism of ovel mechanism of alcohol-induced hepatic stellate cell activation via secreted phosphoprotein 1 pathway. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, S22.	0.4	0



#	ARTICLE	IF	CITATIONS
127	A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. <i>Preventive Medicine</i> , 2013, 57, 297-303.	1.6	54
128	Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. <i>International Journal of Drug Policy</i> , 2013, 24, 326-332.	1.6	15
129	Secreted phosphoprotein 1 in chronic liver injury. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, S51-S52.	0.4	0
130	Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary Perinatal and Family Drug Health Service. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2013, 53, n/a-n/a.	0.4	7
131	Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. <i>Australian and New Zealand Journal of Public Health</i> , 2013, 37, 311-315.	0.8	10
132	Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 440-445.	1.5	28
133	Unplanned pregnancy and contraceptive use in women attending drug treatment services. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 146-150.	0.4	85
134	Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. <i>Journal of Urban Health</i> , 2012, 89, 769-778.	1.8	13
135	Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. <i>Substance Abuse and Rehabilitation</i> , 2012, 3, 43.	1.6	3
136	Opportunistic and continuing health care for injecting drug users from a nurse-run needle syringe program-based primary health care clinic. <i>Drug and Alcohol Review</i> , 2012, 31, 114-115.	1.1	7
137	Effect of pegylated interferon- $\alpha$ 2a treatment on mental health during recent hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 957-965.	1.4	38
138	Individual versus team-based case management for clients of opioid treatment services: An initial evaluation of what clients prefer. <i>Drug and Alcohol Review</i> , 2012, 31, 499-506.	1.1	7
139	Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. <i>Journal of Hepatology</i> , 2011, 55, 76-85.	1.8	53
140	Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. <i>Australian Journal of Primary Health</i> , 2011, 17, 10.	0.4	21
141	Pathogenesis of alcohol-induced liver disease: Classical concepts and recent advances. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1089-1105.	1.4	138
142	A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 294-295.	0.8	5
143	Training in Addiction Medicine in Australia. <i>Substance Abuse</i> , 2011, 32, 115-119.	1.1	7
144	Problem drinking - detection and assessment in general practice. <i>Australian Family Physician</i> , 2011, 40, 570-4.	0.5	2

#	ARTICLE	IF	CITATIONS
145	Problem drinking--management in general practice. <i>Australian Family Physician</i> , 2011, 40, 576-82.	0.5	0
146	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. <i>European Journal of Epidemiology</i> , 2010, 25, 143-148.	2.5	74
147	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. <i>Hepatology</i> , 2010, 51, 1463-1465.	3.6	26
148	Alcohol, Signaling, and ECM Turnover. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 4-18.	1.4	33
149	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. <i>Addiction</i> , 2010, 105, 329-334.	1.7	20
150	Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. <i>Addiction</i> , 2010, 105, 2085-2094.	1.7	203
151	Forming a national multicentre collaboration to conduct clinical trials: Increasing high-quality research in the drug and alcohol field. <i>Drug and Alcohol Review</i> , 2010, 29, 469-474.	1.1	6
152	Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. <i>Drug and Alcohol Review</i> , 2010, 29, 518-524.	1.1	31
153	Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. <i>Medical Journal of Australia</i> , 2010, 192, 496-500.	0.8	43
154	Clinical Predictors of Outcome from an Australian Pharmacological Relapse Prevention Trial. <i>Alcohol and Alcoholism</i> , 2010, 45, 520-526.	0.9	9
155	Expectancy in Double-Blind Placebo-Controlled Trials: An Example from Alcohol Dependence. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 167-171.	4.0	29
156	Charles S. Lieber, 1931-2009. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 941-942.	1.4	1
157	Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence. <i>Drug and Alcohol Review</i> , 2009, 28, 222-229.	1.1	9
158	Understanding and Treating Patients With Alcoholic Cirrhosis: An Update. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 1136-1144.	1.4	25
159	Management of injecting drug users admitted to hospital. <i>Lancet, The</i> , 2009, 374, 1284-1293.	6.3	99
160	Criminal Justice And Addiction Treatment: Best Practices in Addiction Treatment In the Criminal Justice System. <i>Canadian Journal of Addiction</i> , 2009, 1, 18.	0.2	0
161	Inflammation and Repair in Viral Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1468-1487.	1.1	31
162	The influence of alcohol and tobacco use in orthopaedic inpatients on complications of surgery. <i>Drug and Alcohol Review</i> , 2008, 27, 55-64.	1.1	26

#	ARTICLE	IF	CITATIONS
163	Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. <i>Drug and Alcohol Review</i> , 2008, 27, 115-122.	1.1	33
164	Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?. <i>Addiction</i> , 2008, 103, 953-959.	1.7	57
165	Down-regulation of liver GalT <sup>2</sup> 1, 4GlcNAc 1±2, 6-sialyltransferase gene by ethanol significantly correlates with alcoholic steatosis in humans. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1663-1668.	1.5	22
166	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. <i>Journal of Hepatology</i> , 2008, 48, 614-627.	1.8	48
167	Unplanned admissions to two Sydney public hospitals after naltrexone implants. <i>Medical Journal of Australia</i> , 2008, 188, 441-444.	0.8	23
168	Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. <i>Lancet, The</i> , 2007, 370, 1915-1922.	6.3	611
169	“I’ll never touch it again, doctor!” harmful drinking after liver transplantation. <i>Hepatology</i> , 2007, 46, 1302-1304.	3.6	5
170	Transmission of hepatitis C virus by needle-stick injury in community settings. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1882-1885.	1.4	17
171	Detection of and intervention for excessive alcohol and tobacco use among adult hospital in-patients. <i>Drug and Alcohol Review</i> , 2007, 26, 127-133.	1.1	24
172	Pre-operative screening for excessive alcohol consumption among patients scheduled for elective surgery. <i>Drug and Alcohol Review</i> , 2007, 26, 119-125.	1.1	22
173	Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. <i>Drug and Alcohol Review</i> , 2007, 26, 231-239.	1.1	30
174	Intrahepatic gene expression in human alcoholic hepatitis. <i>Journal of Hepatology</i> , 2006, 45, 306-320.	1.8	65
175	Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. <i>Addiction</i> , 2006, 101, 1451-1462.	1.7	143
176	Challenge for doctors and policy makers. <i>BMJ: British Medical Journal</i> , 2006, 332, 277.2-278.	2.4	0
177	THE EFFECTIVENESS OF A TAILORED INTERVENTION FOR EXCESSIVE ALCOHOL CONSUMPTION PRIOR TO ELECTIVE SURGERY. <i>Alcohol and Alcoholism</i> , 2006, 41, 643-649.	0.9	37
178	PREDICTORS OF RELAPSE TO HARMFUL ALCOHOL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Alcohol and Alcoholism</i> , 2006, 41, 278-283.	0.9	113
179	The medical complications of heroin use. <i>Current Opinion in Psychiatry</i> , 2005, 18, 257-263.	3.1	13
180	The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial.. <i>Journal of Studies on Alcohol and Drugs</i> , 2005, 66, 833-841.	2.4	31

#	ARTICLE	IF	CITATIONS
181	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. <i>Journal of Infectious Diseases</i> , 2004, 189, 1846-1855.	1.9	147
182	Genetic disorders in pancreatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 939-939.	1.4	0
183	The Treatment of Drinking Problems: a Guide for the Helping Professions. <i>Addiction</i> , 2004, 99, 135-135.	1.7	0
184	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. <i>Journal of Urban Health</i> , 2004, 81, 448-452.	1.8	21
185	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. <i>Pancreatology</i> , 2004, 4, 82-89.	0.5	45
186	General practitioners' diagnostic skills and referral practices in managing patients with drug and alcohol-related health problems: implications for medical training and education programmes. <i>Drug and Alcohol Review</i> , 2003, 22, 417-424.	1.1	34
187	Quality of life of women living with hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1329-1331.	1.4	2
188	Pathogenesis and management of alcoholic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1332-1344.	1.4	61
189	Gene Expression Profiling of Alcoholic Liver Disease in the Baboon ( <i>Papio hamadryas</i> ) and Human Liver. <i>American Journal of Pathology</i> , 2003, 163, 2303-2317.	1.9	78
190	SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. <i>Journal of Proteomics</i> , 2003, 55, 53-66.	2.4	61
191	NSW Alcohol Summit: getting a better grip on our favourite drug. <i>Medical Journal of Australia</i> , 2003, 179, 521-522.	0.8	0
192	Antioxidants status and physical fitness in seniors aerobically trained and supplemented with a multivitamin drink. <i>Forum of Nutrition</i> , 2003, 56, 261-2.	3.7	1
193	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. <i>Medical Journal of Australia</i> , 2001, 174, 183-184.	0.8	57
194	Alcohol and the Pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	1.4	13
195	Alcohol and the pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	1.4	4
196	Metabolism of Alcohol by the Human Stomach. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 407-408.	1.4	14
197	Transmission of hepatitis C within Australian prisons. <i>Medical Journal of Australia</i> , 1999, 171, 31-33.	0.8	51
198	Activation of Pancreatic Stellate Cells in Human and Experimental Pancreatic Fibrosis. <i>American Journal of Pathology</i> , 1999, 155, 1087-1095.	1.9	382

#	ARTICLE	IF	CITATIONS
199	Alcohol and the pancreas. <i>Addiction Biology</i> , 1998, 3, 137-150.	1.4	23
200	Cystic fibrosis genotypes and alcoholic pancreatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 496-499.	1.4	57
201	Metabolism of ethanol by rat pancreatic acinar cells. <i>Translational Research</i> , 1998, 132, 294-302.	2.4	87
202	CLINICAL UPDATE: Management of acute pancreatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 189-197.	1.4	9
203	Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. <i>Life Sciences</i> , 1996, 58, 485-492.	2.0	16
204	Expression of the Gene for Multidrug-Resistance-associated Protein and Outcome in Patients with Neuroblastoma. <i>New England Journal of Medicine</i> , 1996, 334, 231-238.	13.9	295
205	Gastric metabolism of ethanol in Syrian golden hamster. <i>Digestive Diseases and Sciences</i> , 1995, 40, 2712-2716.	1.1	8
206	Relationship between hepatitis C virus subtypes and clinical features of liver disease seen in alcoholics. <i>Journal of Hepatology</i> , 1995, 22, 130-134.	1.8	15
207	Spontaneously Occurring Antibodies to Parathyroid Hormone*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1744-1749.	1.8	10
208	Management of alcohol and other drug issues in Special Health Accommodation during the COVID-19 Delta variant outbreak in Sydney, 2021. <i>Drug and Alcohol Review</i> , 0, , .	1.1	1